Compare iShares MSCI Malaysia ETF (EWM) vs Novartis AG (NVS) Price & Performance

EWM (iShares MSCI Malaysia ETF) trades at $28.18, up 0.28% with a bullish technical signal from moving averages. The ETF offers concentrated exposure to Malaysia's financial (54%) and industrial (21%) sectors, benefiting from data center expansion and tourism initiatives. Key support and resistance cluster around $28, with neutral oscillators suggesting balanced momentum.

Outlook remains positive due to Malaysia's structural growth drivers, though financial ratios are unavailable. Risks include energy supply constraints and regional currency volatility. Institutional sentiment leans bullish with 11 buy signals, but investors should monitor Malaysia's economic policies and global macro conditions.

Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.

The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.